Botox Maker Argues Rival Drug Was Developed With Stolen Secrets
- Allergan, Medytox seek to block imports of competitive product
- Daewoong accused of stealing process to make Botox rival
Photographer: Jason Alden/Bloomberg
This article is for subscribers only.
Allergan Plc and partner Medytox Inc. are seeking to block U.S. imports of a new rival to the wrinkle-treatment Botox, claiming it was developed using stolen manufacturing secrets and turncoat former employees.
Daewoong Pharmaceuticals Co. and Evolus Inc., which denied the allegations, expect to begin North American sales in the coming months of their competing drug called DWP-450. Medytox contends a former employee handed over to Daewoong the results of its “meticulous, time-consuming, and expensive research” into a new process to make a treatment based on the deadly botulinum toxin, according to the filed Wednesday at the U.S. International Trade Commission in Washington.